Achievements

350 million treatments of Coartem® Dispersible delivered to over 50 countries

1st potential new medicine for relapsing malaria in more than 60 years completes phase III trials with GSK

MMV048 progresses to phase IIa as new formulation with 3x greater exposure identified

18,000 health-care workers trained to administer injectable artesunate for severe malaria

Pyramax® Granules added to the WHO list of prequalified medicines

1st rectal artesunate suppository to be quality assured

180 Pathogen Boxes shipped

73 million courses of SP+AQ shipped to countries in West Africa's Sahel region

19 new malaria drug targets validated since 1999

8 potential new medicines in clinical development prioritizing treatment for vulnerable populations and supporting malaria eradication

USD 1 = USD 3.5 of investment impact thanks to direct and in-kind support from partners

160 active partners in MMV's network, working to help defeat malaria

100 million vials of Artesun® delivered to treat children with severe malaria

 

>90% of severe malaria cases now treated with injectable artesunate in preference to quinine

MMV wins Open Data Innovation Award for work on the Malaria Box
Dr David Reddy, CEO, MMV and Dr Bernard Pécoul, CEO, DNDi

2 ACTs developed by DNDi and partners transitioned to MMV

More than 200,000 doses of Eurartesim® distributed in two ground-breaking mass drug administration pilots

Key landmarks for MMV-supported medicines

Key Achievements over MMV's first 15 years